Scribe Therapeutics Inc. (NASDAQ:SCTX - Get Free Report) was the recipient of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 1,671,740 shares, a growth of 49.5% from the October 15th total of 1,118,447 shares. Currently, 8.8% of the company's stock are sold short. Based on an average daily trading volume, of 417,041 shares, the days-to-cover ratio is currently 4.0 days.
Scribe Therapeutics Stock Performance
NASDAQ SCTX traded up $0.01 during trading on Tuesday, reaching $15.38. 116,279 shares of the company traded hands, compared to its average volume of 357,844. The stock has a 50 day moving average price of $20.86. The firm has a market capitalization of $291.17 million and a P/E ratio of -1.41. Scribe Therapeutics has a 1-year low of $13.50 and a 1-year high of $39.60.
Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.26). The firm had revenue of $1.64 million during the quarter. Equities research analysts forecast that Scribe Therapeutics will post -3.68 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently weighed in on SCTX. Wells Fargo & Company assumed coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an "overweight" rating and a $60.00 price objective on the stock. Zacks Research upgraded Scribe Therapeutics to a "hold" rating in a research note on Tuesday, September 1st. Wall Street Zen upgraded shares of Scribe Therapeutics to a "hold" rating in a research note on Saturday, August 1st. HC Wainwright initiated coverage on shares of Scribe Therapeutics in a report on Monday, August 31st. They issued a "buy" rating and a $60.00 price target on the stock. Finally, Weiss Ratings initiated coverage on shares of Scribe Therapeutics in a research note on Tuesday, October 20th. They issued a "sell (e-)" rating for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Scribe Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $51.75.
View Our Latest Stock Report on Scribe Therapeutics
Institutional Trading of Scribe Therapeutics
A number of large investors have recently bought and sold shares of SCTX. Baker BROS. Advisors LP bought a new position in shares of Scribe Therapeutics during the third quarter valued at $12,675,000. State Street Corp bought a new stake in shares of Scribe Therapeutics in the 3rd quarter worth about $3,150,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Scribe Therapeutics in the 3rd quarter worth about $398,000.
About Scribe Therapeutics
(
Get Free Report)
Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scribe Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scribe Therapeutics wasn't on the list.
While Scribe Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.